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Summary Hepatocellular carcinoma (HCC) is a common lethal disease in Asia and there is no effective chemotherapy. Identification of new
effective drugs in the treatment of inoperable HCC is urgently need. This is a phase 11 clinical study to investigate the efficacy, toxicity and
pharmacokinetics of paclitaxel in HCC patients. Twenty patients with measurable, unresectable HCC, normal serum bilirubin, normal bone
marrow and renal functions were studied. Paclitaxel 175 mg rrr2 was given intravenously over 3 h every 3 weeks. No complete or partial
responses were observed. Five patients had stable disease. Major treatment toxicities (grade 3-4) were neutropenia (25%), thrombo-
cytopenia (15%), infection (10%) and allergy (10%). Treatment-related deaths occurred in two patients. The median survival was 12 weeks
(range 1-36). Paditaxel is metabolized by the liver and the pharmacokinetcs of paclitaxel in cancer patients with liver involvement or
impairment may be important clinicalty. Pharmacokinetic study was completed in 13 HCC patients. The pacitaxel area under the curve was
significantly increased (P < 0.02), clearance decreased (P < 0.02) and treatment-related deaths increased (P = 0.03) in patients with hepatic
impairment. In conclusion, paclitaxel in this dose and schedule has no significant anti-cancer effect in HCC patients. Paclitaxel should be used
with caution in cancer patients with liver impairment.
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Hepatocellular carcinoma (HCC) is among the most common
malignancies in the world. The incidence rate is as high as 34
persons per 100 000 per year in some high-incidence areas in Asia
such as China (Muir. 1989). HCC is strongly associated with
chronic hepatitis B virus (HBV) infections (Tong et al. 1971). The
majority of HCC patients present with inoperable disease and
systemic chemotherapy is ineffective and the prognosis is poor
(Venook. 1994a). Identification ofnew effective chemotherapy for
HCC is urgently needed.
Paclitaxel is one ofthe most active new anti-cancer drugs intro-
duced in cancer chemotherapy in the last decade. Paclitaxel is
active as salvage therapy in advanced ovarian, head and neck,
breast and lung cancer patients (Guchelaar et al. 1994; Rowinsky.
1994). The results achieved in these cancers are impressive
because heavily pretreated and refractory patients responded to
paclitaxel. The anti-cancer activity of paclitaxel in HCC is
unknown.
Paclitaxel is metabolized by the liver. Plasma paclitaxel concen-
trations decrease rapidly after the completion ofintravenous infu-
sion. This initial decline is followed by a more prolonged terminal
phase and extensive extravascular distribution of the drug.
Paclitaxel exhibits non-linear. saturable pharmacokinetics over a
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wide range of doses with a variety of infusion schedules. Several
mathematical pharmacokinetic models have been generated to
attempt to describe these findings (Rowinsky et al. 1993a;
Sonnichsen et al. 1994). Paclitaxel may be retained at high blood
concentrations for prolonged periods oftime in patients with liver
impairment with potential increase in toxicity.
As patients with advanced HCC usually have various degrees of
liver impairment because of chronic hepatitis infection, cirrhosis
and liverreplacement by tumour, an assessment ofpaclitaxel phar-
macokinetic parameters in such patients might be informative.
Here. we report the results ofa phase II and pharmacokinetic study
ofpacitaxel in the treatment ofpatients with unresectable HCC.
PATIENTS AND METHODS
Eligibility
Patients were required to have measurable, pathologically
confirmed, inoperable or metastatic HCC. Patients unsuitable for
biopsy because of prolonged prothrombin time secondary to
impaired liver function must have had alpha-fetoprotein (AFP)
> 400 ng ml- and typical hepatic angiogram findings of HCC.
Patients had Eastem Cooperative Oncology Group (ECOG)
performance status of 0-2 (Oken et al. 1982), blood granulocyte
count of > 1500 mm-3 platelet count of > 100 000 mm-3. serum
creatinine < 2 mg dl-', bilirubin < 1.6 mg dl-' and aspartate amino-
transferase (AST) <5 times normal. All patients were screened for
hepatitis B and C. This study was approved by the institutional
review board. Informed consent was obtained from every patient.
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Treatment plan
Pacitaxel 175 mg m-' was given as a continuous intravenous infu-
sion over 3 h in 5% dextrose every 3 weeks. To reduce the risk of
hypersensitivity reactions. all patients were premedicated with
20 mg of oral dexamethasone 12 h and 6 h before chemotherapy.
300 mg of intravenous cimetidine and 50 mg of intravenous
diphenhydramine 1 h before chemotherapy. Pacitaxel was
reduced to 135 mg m-2 for grade 4 myelosuppression. Pacitaxel
was increased to 200 mg m-2 if the white blood cell (WBC) nadir
was > 1000 mm', and the platelet nadir was > 100000mm
Pacitaxel therapy was continued until progressive disease.
Patient evaluation and reponse criteria
Patients were evaluated every 3 weeks. Response and toxicity were
assessed according to ECOG criteria (Oken et al. 1982). All
response data were reviewed by an independent radiologist. The
indocyanine green (ICG) retention test (Caesar et al. 1961) was
performed in each patient to assess the liverfunction: a 21-G angio-
catheter was inserted into the antecubital vein ofthe forearm and a
baseline venous sample was taken. ICG (0.5 mg kg-1) (5 mg ml-')
was injected into the right antecubital vein. Then. 5 ml of blood
was collected at 5. 10 and 15 min from the left antecubital vein.
Pharmacokinetic sample collection
Venous blood samples were obtained from each patient at the
following times from the start of paclitaxel infusion: before infu-
sion and 10 min 1.5. 3. 3.25. 5. 6. 15. 24 and 48 h after infusion.
The plasma was stored at -20°C until analysis. Urine was
collected in two time intervals (0-24 h and 24-48 h after the
paclitaxel infusion) and stored at -20°C until analysis.
Bioanalytic methods
Solid-phase extraction and an isocratic high-performance liquid
chromatography (HPLC) method was used for the quantitation of
pacitaxel in plasma and urine according to previously published.
validated methodology (Willey et al. 1993). A standard curve
covering the concentration range 1-800 ng ml-1 was used for
patient samples. Quantitation of pacitaxel in plasma was
performed by comparing chromatographic peak heights from
patient samples with those obtained from standards containing
known amounts of pacitaxel. Quantitation of paclitaxel in urine
was accomplished using peak areas.
Pharmacokinetic analysis
Plasma concentration (C) vs time (t) data were analysed using non-
compartmental methods using the MENU program (Farmen et al.
1987). The observed peak plasma concentraion (Cr) and the time
at which it occurred(t.) were tabulated The area under the plasma
concentration (AUC) vs time curve from time zero to infinity.
AUC,O(,,. and the area under the first moment curve. AUMC
(Ct vs t), was calculated using log-trapezoidal summations and the
extrapolation methods described by Riegelman and Coffier (1984).
The teminal slope of the plasma concentration vs time curve was
determinedby log-linearregression analysis to the point where mean
square error was minimized; at least three data points were
used. Equations used to estimate values for the phanmaokinetic
Table 1 Patient characteristics
Patient number
Age, median (range)
Sex M/F
ECOG performance status
0/1/2
Cirrhosis of liver
HBsAg poitive
Anti-HCV positive
Alcoh
Cryptogenic
AJCC stage llAV
Previous chemotherapy
AFP > 400 ng ml-1 (normal < 8)
Bilirubin < 1.6 mg dVt (normal 0.2-1.6)
AST > 45 IU h1 (normal 5-45)
AJbumin < 3.5 g dFh (normal 3.7-5.3)
Prothrombin bme (INRa) > 1.25 (normal < 1.25)
Ascites
Main portal vein thrombosis
Extrahepatic metastasis
20
64 (30-73)
20/0
7/10/3
20
15
1
2
2
15/5
0
13
20
20
7
6
3
6
aINR, intermaonal normalized ratio.
Table 2 Toxicites in 20 patients
Grade oftoxicitr
Number with 1 2 3 4
Vomiting 0 0 1 (5°) 0
DiarThoea 0 0 0 1 (50o)
Mucositis 2 (10%) 1 (5o%) 1 (5°0) 0
Neutropenia 2 (10%) 5 (25%) 3 (15%) 2 (10o)
Thrombocytopenia 2 (10%) 1 (5%) 2 (10o) 1 (5%)
Infection 0 2 (10%) 0 2 (10%)
Neuropathy 7 (35%) 1 (5%) 0 0
Cardiac toxicity 0 0 0 0
Alopecia 2 (10%) 3 (15%) 0 0
Myalgia 0 1 (5o) 0 0
Allergy 2 (10%) 1 (5%) 1 (50o) 1 (50%')
aECOG toxicity criteria.
parameters, trminal elimination half-life (t1j. total body clearance
(CLT). mean residence time (MRT) and apparent volume of
distribution at steady state (V>) are shown below: t1, = In-424:
CLT = doseIAUC,,,,; MRTI =AUMCI,_/AUC,,__. MRTIJ =
MRT - TV2; and VI, = CLT xMRT. In the t,,, equation, the
variable '(3 is the slope ofthe terminal elimination cur e. The term
TI in theMRT,, equation is the length ofthe infusion (in hours).
Statistical methods
The Simonphase H clinical trials design method was used (Simon.
1989). in which if the response rate was < 3 of 19 patients in the
first stage, then the trial would be terminated. This design has an a
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Figure 1 Overall survival curve of the 20 HCC patients treated with
paditaxel
of0.1 and 3 of0.1. Survival estimations were performed according
to the Kaplan-Meier method (Kaplan and Meier, 1958). Paclitaxel
pharmacokinetic parameters were compared using the Mann-
Whitney U-test. Treatment-related deaths were compared using
Fisher's exact test (one-sided).
RESULTS
Patient characteristics are listed in Table 1. Twenty patients were
studied between November 1993 and September 1994. All patients
had AJCC (American Joint Committee on Cancer) stage Ill or IV
HCC (Beahrs et al, 1992). The median age was 64 years. All
patients had cirrhosis and elavation of AST but normal bilirubin.
Seven patients (35%) had hypoalbuminaemia Six patients (30%)
had prolonged prothrombin time. The median serum AST level
was 96 WU 1-' (range 46-224: normal 5-45 IU 1-1). The median
serum albumin level was 3.7 g dl-I (range 3.0-4.3; normal 3.7-
5.3 g dl-'). The median prothrombin time level was 1.22 interna-
tional normalized ratio (range 1.06-1.40: normal < 1.25). The
median total bilirubin level was 0.9 mg dl-I (range 0.5-1.6; normal
0.2-1.6 mg dlF). The median ICG retention ratio was 11% (range
4-51%; normal < 10%) at 15 min. Four patients (20%) had ICG
retention ratio 20%. Cirrhosis was related to chronic HBV
and/or hepatitis C virus infection in 80% of patients. Two patients
did not return for repeat tumour measurement after one course of
paclitaxel treatment. They felt well after treatment and went to
China to visit their respective families and did not return to
Taiwan. Two patients died of grade 4 neutropenic septicaemia 9
and 16 days after the first cycle of paclitaxel treatment. Sixteen
Table 3 Individual non-compartnental pharmuacoknetic parameters
Patient Dose Cycle C. AUCf,_> t12 CLT V. Per cent urinary ICG
number (mg m7- number (igg mF') (uig h ml-') (hour) (I h-' m<-) (I m-2) ecovey (%)
1 175 1 5.75 20.67 18.7 8.60 55.1 3.85 3
2 175 1 4.27 24.30 11.6 7.38 51.7 9.82 5
200 2 6.71 34.78 11.6 5.77 39.9 2.61
3 175 1 4.78 21.50 8.3 8.21 46.9 12.15 11
175 2 3.67 13.72 9.9 16.86 83.00 5.89
200 3 6.09 21.96 12.4 9.11 56.34 10.61
4 175 1 5.60 24.15 14.2 7.25 49.4 9.96 20
200 2 5.81 30.36 13.6 6.59 47.80 7.75
200 3 9.60 40.52 14.3 4.86 34.70 5.89
5 175 1 4.42 23.45 10.9 7.53 50.6 6.76 13
6 175 1 3.54 16.56 9.5 10.57 55.7 5.28 4
175 2 3.22 10.76 6.9 16.26 80.3 3.92
7 175 1 4.80 22.56 13.6 7.69 73.9 9.93 31
8 175 1 4.14 20.67 10.4 8.16 56.2 4.35 17
200 2 3.89 21.92 11.5 9.12 72.2 12.24
9 175 1 3.87 17.62 8.3 9.88 70.3 2.09 18
10 175 1 3.56 17.99 11.9 9.72 59.5 4.83 12
11 175 1 4.48 19.16 5.3 9.12 40.1 3.60 5
200 2 5.66 24.46 10.6 8.13 51.3 0.65
12 175 1 4.19 33.12 9.8 5.29 56.9 11.44 23
13 175 1 3.94 16.79 12.2 10.14 141.2 5.44 14
Mean 175 1 4.41 21.43 11.1 8.43 62.1 6.88
+ SD n= 13 0.69 4.43 3.3 1.46 25.4 3.34
Mean 175 2 3.45 12.24 8.4 14.56 81.7 4.91
n = 2
Mean 200 2 5.51 27.88 11.8 7.40 52.8 5.81
±SD n = 4 1.18 5.80 1.2 1.51 13.8 5.23
Mean 200 3 7.84 31.24 13.4 6.98 45.5 8.25
n = 2
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patients were evaluable for response. The median number of
courses ofpaclitaxel chemotherapy given was two (range 1-7).
There was no complete response (CR) or partial response (PR).
There were five stable disease (SD) and 11 progressive disease
(PD). The overall survival of patients after paclitaxel teatment is
shown in Figure 1. The median survival was 12 weeks (range
1-36). All patients died within 36 weeks after paclitaxel therapy.
The median survival ofSD patients (14 weeks; range 8-36) was not
significantly different from the PDpatients (12 weeks; range 8-24).
The toxicities in 20 patients after pacitaxel therapy are listed in
Table 2. The major toxicities (grade 3-4) were neutropenia 25%,
thrombocytopenia 15%, infection 10%, allergy 10%, diarrhoea
5%, vomiting 5% and mucositis 5%. Two patients (10%) with
grade 4 neutropenia died ofneutropenic septicaemia 9 and 16 days
after pacitaxel teatment. Other toxicities were mild and tolerable.
The paclitaxel pharmacokinetic results are summarized in Table
3. A total of 13 patients were sampled for pharmacokinetics during
the first course of pacitaxel at a dose of 175 mg m-2. Six of these
patients underwent further pharmacokinetic sampling during their
second cycle oftreatment (two at a dose of 175 mg m-2and four at
a dose of200 mg m-2) and two patients were sampled for pharma-
cokinetics during their third cycle ofpacitaxel ratment at a dose
of 200 mg M-2. For the first cycle of pacitaxel treatment in the
13 patients who were studied for pharmacokinetics at a dose of
175 mg m-2, the mean C,, was 4.41 ± 0.69gg ml' AUC<,
was 21.42 ± 4.43 (jigh ml -1); t,, was 11.1 ±3.3h; CLT was
8.43 ± 1.46 1 h-'m-2and V was 62.1 ±25.41m-2. ss
In 10 patients whose baseline ICG retention ratio was < 20% at
15 min, the mean paclitaxel AUC,O<| was 19.9 ±2.7jgh ml- and
CLT was 8.9 ± 1.11 h- m72. In three patients whose baseline ICG
retention ratio was .20% at 15 min, the mean paclitaxel AUC(¢O_
was 26.6 ±5.7 gghml-' andCLTwas6.7 ± 1.3 1 h-' m-2 (Table4)
The increase in paclitaxelAUC(,Q-) (P<0.02) and decrease in CLT
(P < 0.02) in patients with ICG retention ratio > 20% at 15 min
were statistically significant.
The pacitaxel toxicity according to ICG retention ratio < or
> 20% at 15 min is shown in Table 5. Grade 3-4 infection and
reatment-related deaths were associated with an ICG ratio >20%.
Paclitaxel teatment-related deaths occurred in two out of four
(50%) patients with an ICG retention ratio .20% at 15 min and no
deaths occurred in 16 patients with an ICG retention ratio <20% at
15 min (P = 0.03). One of the treatment-related deaths, patient
number 12, had pharmacokinetic sampling and had the highest
paclitaxelAUC(O,, and the lowest CLT in this study (Table 3).
There were no significant differences in pacitaxel pharmacoki-
neticp;armeters in the 13 patients when baseline ASTvalue above or
below two times normaL presence or absence of ascites, AFP above
or below 400 ng m}', albumin level above or below 3.5 g dV1 or
prodbronbin time above orbelow 1.25 times control were compared.
DISCUSSION
The results of this study indicate that paclitaxel may have no
significant anti-cancer activity against HCC. Despite the excellent
anti-cancer effects of paclitaxel in the teatment of various
cancers, no response was observed in HCC patients after paclitaxel
chemotherapy of 175-200mg m-2 over 3h in this study. The
median survival ofHCC patients after paclitaxel chemotherapy in
this study was 12 weeks and the absence of survivors after 36
weeks suggest that paclitaxel may have no major clinical impact
Table 4 Pacitaxel phamrnacoinetic parameters and indocyanine green
(ICG) test in 13 pabents
ICG < 20% (n = 10) ICG > 20%(n= 3)
C,, (gg r ml[1) 4.27 ± 0.65 4.86 ± 0.70
AUC,__) (rIg h rn'-1) 19.9 ± 5.7a 26.6 ± 5.7a
T1,2(hr) 10.7± 3.5 12.5±2.4
CLT (I h-'r -2) 8.9±1.1a 6.7±1.3a
V, (Irn-2) 62.7±28.7 60.1 ±12.6
Percent urinary recovery 5.81 ± 3.0 10.4± 0.8
ap< O.o2.
Table 5 Pacitaxel toxicity accordig indocyarine green (ICG) retention rabo
in 20 pabents
Toxdcites ICG < 20% ICG . 20%
(.grade3) (n= 16) (n=4)
Neutopnia 2 (12.5%) 3 (75%)
Thrombocytopenia 1 (6.25%) 2 (50%)
Infection 0 2 (50%)a
Treatment-related deaths 0 2 (50%)p
VOMin 1 (6.25%) 0
Diarrhoea 0 1 (25%)
Mucositis 0 1 (25%)
Alergy 1 (6.25%) 1 (25%)
ap= 0.03(F,hs exacttest, one-sided).
on the survival of HCC patients. These results appear similar to
median survival of 13 weeks in HCC patients teated by ineffec-
tive chemorapy reported by Lai et al (1989). Investigation of
other new effective chemotherapeutic agents for the treatment of
HCC is urgently needed.
The mechanism of drug resistance of HCC to pacitaxel is
uncertain. One possibility may be the intrinsic high expression of
the multiple drug resistance (mdr) gene in human hepatic tissue
and bepatoma (Goldstein et al, 1989). Pacitaxel resistance in
cancer patients may be associated with high expression ofthe mdr
gene (Horwitz et al, 1993; Webster et al, 1993).
The incidence of 25% grade 3-4 neutropenia in this study is
similar to the 27-29% reported when paclitaxel was given in the
same dose and schedule to treat ovarian cancer patients with
normal liver function (Rowinsky et al, 1993b; Guastalla et al,
1994). Overall toxicities of paclitaxel in this study also appear
similar to other pacitaxel studies, but the 10% treatment-related
deaths in this studyappeared higherthan reported (Rowinsky et al,
1993b; Chan et al, 1994; Gianni et al, 1994; Guastalla et al, 1994).
As pacitaxel is metabolized by the cytochronxe P450 system
(Jamis-Dow et al, 1995), patients with impaired liver function may
be at increased risk of pacitaxel toxicities. Indeed, Wilson et al
(1994) reported that five patients with metastatic liver disease
and alanine aminoransferase >2 times normal had significantly
decreased paclitaxel clearance andincreasedpaclitaxel toxicity when
paclitaxel was given by a 96-h infusion at doses ranging from 120 to
160mg m-2. Venook et al (1994b) repore significant paclitaxel
0 CancerResearch Campaign 1998 Brffish JoumalofCancer(1998) 78(l), 34-3938 YChao etal
toxicities in cancer patients with AST > 2 times nmal with or
without hyperbilirubinaemia receiving paclitaxel as a 24-h infusion
and recommended reduction i the paclitaxel dose in these patents.
No treatment-related deaths were mentioned in these two absts.
This is the first report of the relationship between paclitaxel
toxicity, pharmacokinetics and liver impairment when paclitaxel
was given as a 3-h infusion. All patients in this study had normal
bilirubin but extensive replacement of the liver by HCC and
cirrhosis. Most patients had some hepatic impairment, as indicated
by abnormal transaminase, albumin or prothrombin time. These
liver function tests were of no predictive value in paclitaxel clin-
ical toxicity or altered paclitaxel pharmacokinetic in this study.
Accurate prediction of severe paclitaxel toxicity in patients with
liver impairment is clinically important. A more sensitive or
predictive test will be useful, especially in patients with normal
bilirubin but subclinical impairment ofliver function.
The ICG retention test is a simple and accurate liver function
test to determine liver function as well as hepatic blood flow
(Cherrick et al, 1960; Caesor et al, 1961). The ICG retention test
has a good prognostic value in cirrhotic patients and is widely
accepted for measuring functional reserve in chronic liver
diseases. The ICG retention test is also useful in assessing hepatic
functional reserve preoperatively to predict successful hepatic
resection in HCC patients (Okamoto et al, 1984). In our hospital,
the ICG retention ratio < 20% at 15 min has been used for the last
8 years to select HCC patients with adequate hepatic functional
reserve for hepatic surgery (Jwo et al, 1992; Wu et al, 1996). The
ICG retention ratio .20% at 15 min may be predictive of
increased paclitaxel toxicities including treatment-related deaths
associated with liver impairment and increased AUC and reduced
clearance ofthe drug.
These findings may be important clinically because paclitaxel is
usually given at full dose to patients with normal bilirubin and
some patients may have significant toxicity. We recommend that
paclitaxel dose reduction should be considered in patients with
normal bilirubin but subclinical hepatic impairment High-risk
patients with extensive replacement of liver by tumour, cirrhosis,
chronic HBV infection, etc. may be identified by an additional
liver function test such as the ICG retention test. Further clinical
investigation of paclitaxel pharmacokinetics and liver function
may be worthwhile.
In conclusion, paclitaxel had no significant anti-cancer activity
in patients with advanced hepatocellular carcinoma when adminis-
tered at a dose of 175-200 mgm-2 using a 3 h intravenous infu-
sion. ICG retention . 20% at 15 min appeared to identify patients
with normal bilirubin and subclinical liver impairment and to
predict altered pacitaxel pharmacokinetics and increased pacli-
taxel clinical toxicities, including tratment-related deaths.
Paclitaxel should be used with caution in patients with hepatic
dysfunction. Further clinical investigation ofpaclitaxel pharmaco-
kinetics in patients with liver impairment is warranted.
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